The genomics market is projected to reach USD 85.09 billion by 2030 from USD 47.07 billion in 2025, registering a CAGR of 12.6% from 2025 to 2030. The growth of the genomics market is driven by increasing government funding for genomics projects, a rising prevalence of viral and inherited disorders, advancements in NGS platforms, and the expansion of applications in genomics.
Browse in-depth TOC on " Genomics Market "
350 - Tables
50 - Figures
310 - Pages
By offerings, the genomics market is segmented into products and services. The products segment accounted for the largest share of the genomics market in 2024. The large share of the products segment can be attributed to innovations in genomics technology, such as long-read sequencing (LRS), single-cell genomics, and CRISPR technology, which have expanded product offerings and applications, thereby boosting demand for specialized products and technologies.
By study type, the genomics market has been segmented into functional genomics, biomarker discovery, pathway analysis, epigenomics, and other study types. In 2024, the functional genomics segment accounted for the largest market share. This segment is also expected to experience the fastest growth during the forecast period due to its essential role in identifying potential drug targets, particularly in fields such as cancer and genetic disorders. This critical nature is driving its widespread adoption in pharmaceutical research. Meanwhile, the biomarker discovery segment holds the second-largest share of the market.
By geography, the genomics market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific is expected to register the fastest growth in the genomics market during the forecast period, driven by increasing government funding for genomic research, expanding healthcare infrastructure, and the rising adoption of precision medicine initiatives across major countries, including China, Japan, and India. Growing investments by global and regional players, coupled with a large patient pool for genetic and chronic diseases, further accelerate market expansion.
Key players in the genomics market include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), QIAGEN (Germany), Agilent Technologies, Inc. (US), Revvity, Inc. (US), Laboratory Corporation of America Holdings (US), IQVIA Inc. (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), PacBio (US), Oxford Nanopore Technologies Plc. (UK), Takara Bio Inc. (Japan), BGI Group (China), Eppendorf SE (Germany), Merck KGaA (Germany), BD (US), Abbott (US), 10X Genomics, Inc. (US), New England Biolabs (US), Promega Corporation (US), Creative Biogene (US), Novogene Co., Ltd. (China), Helix, Inc. (US), Phalanx Biotech Group (US), and Polaris Genomics (US).
